Anti-VEGFA(bevacizumab biosimiar) mAb Cat. No. BME100061



PRODUCT INFORMATION

Common Name	MVCD1,VEGF,VPF
Synonyms	rhuMAb-VEGF
Conjugate	Unconjugated
Applications	ELISA
Recommended Dilutions	ELISA 1:5000-10000
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Humanized
lgG type	Human IgG1 – kappa
Reactivity	Human
Target	VEGFA
Uniprot ID	P15692
Description	Anti-VEGFA(bevacizumab biosimiar) mAb
Delivery	In Stock
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only

Email: info@dimabio.com Website: www.dimabio.com





Anti-VEGFA (bevacizumab biosimilar) mAb ELISA

0.1µg of Human VEGFA, His Tagged protein per well




Figure 1. ELISA plate pre-coated by 1 µg/ml (100 µl/well) Human VEGFA , His tagged protein ([getskuurl sku="PME100111"]) can bind Anti-VEGFA Neutralizing antibody (BME100061) in a linear range of 0.1-15 ng/ml.

Email: info@dimabio.com Website: www.dimabio.com

